​

CG Oncology Stock (NASDAQ:CGON)

ForecastRevenueOwnershipFinancialsChart
CG Oncology by TradingView

Previous Close

$41.61

52W Range

$14.80 - $46.01

50D Avg

$41.89

200D Avg

$30.50

Market Cap

$3.07B

Avg Vol (3M)

$939.38K

Beta

1.31

Div Yield

-

CGON Company Profile

CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

113

IPO Date

-

Website

CGON Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/ServiceSep 25Jun 25Mar 25
License And Collaboration Revenue$158.00K--
Operating Segments-$52.00K$52.00K

Fiscal year ends in Dec 24 | Currency in USD

CGON Financial Summary

Dec 24Dec 23Dec 22
Revenue-$204.00K$191.00K
Operating Income$-114.67M$-55.45M$-35.25M
Net Income$-88.04M$-48.61M$-35.44M
EBITDA$-114.67M$-55.43M$-35.23M
Basic EPS$-1.41$-15.65$-0.53
Diluted EPS$-1.41$-15.65$-0.53

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

TickerCompany
IRONDisc Medicine, Inc.
AAPGASCENTAGE PHARMA GROUP INTERNATIONAL
TARSTarsus Pharmaceuticals, Inc.
TVTXTravere Therapeutics, Inc.
RAREUltragenyx Pharmaceutical Inc.
CELCCelcuity Inc.
XENEXenon Pharmaceuticals Inc.
LEGNLegend Biotech Corporation
CNTACentessa Pharmaceuticals plc
APGEApogee Therapeutics, Inc.